Yaping Zhu

26PUBLICATIONS
104CO-AUTHORS
ChemotherapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 26, 2026
SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.

|Apr 29, 2026
Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior PARPi Exposure: A Prospective, Open-Label, Single-Arm, Phase II Study.

|Nov 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Lingying Wu, Jing Wang, Qingshui Li

|Oct 23, 2025
Personalized Cancer-Specific Protein-Aptamer Corona for Orthogonal Multiplex Cancer Diagnosis.

Jinlong Fan, Baichuan Jin, Xin Dai

|Jul 23, 2025
Spatially resolved proteomics surveys the chemo-refractory proteins related to high-grade serous ovarian cancer.

Linyuan Fan, Yi Liu, Haichao Zhou

|Nov 25, 2024
Bimodal accurate H2O2 regulation to equalize tumor-associated macrophage repolarization and immunogenic tumor cell death elicitation.

Yan Zhao, Weiheng Kong, Jianqing Zhu

Pageof 5

Frequent Collaborators

6 joint publications

Rutie Yin

5 joint publications

Rongyu Zang

5 joint publications

Ning Li

4 joint publications

Tingyan Shi